<DOC>
	<DOCNO>NCT00000651</DOCNO>
	<brief_summary>To evaluate safety zalcitabine ( dideoxycytidine ; ddC ) alone combination zidovudine ( AZT ) versus AZT alone administer asymptomatic patient CD4 count = &lt; 200 cells/mm3 symptomatic patient CD4 count = &lt; 300 cells/mm3 . To compare effectiveness ddC alone combination AZT versus AZT alone . ddC show demonstrate antiviral effect . AZT show significantly decrease mortality reduce frequency opportunistic infection patient AIDS advance ARC . After 1 year AZT therapy , effectiveness tends diminish patient progress opportunistic infection high mortality rate . Because demonstrated antiviral activity , absence hematologic toxicity , lack cross tolerance laboratory study ddC , study investigate long-term effectiveness ddC patient HIV infection receive AZT therapy warrant .</brief_summary>
	<brief_title>A Randomized , Double Blind , Comparative Study Dideoxycytidine ( ddC ) Alone ddC/AZT Combination Versus Zidovudine ( ZDV ) Alone Patients With HIV Infection Who Have Received Prior ZDV Therapy</brief_title>
	<detailed_description>ddC show demonstrate antiviral effect . AZT show significantly decrease mortality reduce frequency opportunistic infection patient AIDS advance ARC . After 1 year AZT therapy , effectiveness tends diminish patient progress opportunistic infection high mortality rate . Because demonstrated antiviral activity , absence hematologic toxicity , lack cross tolerance laboratory study ddC , study investigate long-term effectiveness ddC patient HIV infection receive AZT therapy warrant . Patients randomly assign 1 3 treatment group . In study arm 1 , patient receive AZT plus ddC placebo . In study arm 2 , patient receive ddC plus AZT placebo capsule . In study arm 3 , patient receive ddC plus AZT . Patients see every week first 8 week monthly thereafter . Patients stratify HIV disease status , length time receive AZT , systemic local Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Patients reach clinical AIDS-defining endpoint offer open-label combination therapy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Zidovudine ( AZT ) = &gt; 300 mg/day 6 week prior study entry . Allowed : Chemoprophylaxis Pneumocystis carinii pneumonia ( PCP ) , candidiasis , herpes . 21 day course adjuvant systemic corticosteroid moderate severe PCP . Maintenance treatment pyrimethamine , sulfadiazine , amphotericin , fluconazole , ketoconazole , acyclovir , ganciclovir , medication tuberculosis Mycobacterium avium patient recover toxoplasmosis , cryptococcosis , candidiasis , herpes virus infection , cytomegalovirus infection , tuberculosis Mycobacterium avium intracellulare . 14 day course metronidazole . Erythropoietin megace clinically indicate . Isoniazid patient peripheral neuropathy entry take pyridoxine = &gt; 50 mg/day concomitantly . Phenytoin patient &lt; grade 2 peripheral neuropathy entry stable phenytoin = &gt; 3 month . Patients must : Ability willingness give inform consent . Written inform consent parent guardian &lt; 18 year old . Been tolerate zidovudine ( AZT ) therapy . Diagnosis HIV infection . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Kaposi 's sarcoma malignancy require therapy . Active opportunistic infection . Peripheral neuropathy manifest complaint moderate pain , burning , numbness , tingle hands/arms feet/legs ; moderate sensory deficit upper low extremity ; motor weakness upper low extremity . Concurrent Medication : Excluded : Other experimental medication . Other antiHIV drug . Biologic response modifier . Cytotoxic chemotherapy . Drugs could cause peripheral neuropathy include phenytoin specifically allow , hydralazine , nitrofurantoin , vincristine , cisplatinum , dapsone , disulfiram , diethyldithiocarbamate . Concurrent Treatment : Excluded : Radiation therapy . Patients follow exclude : Active opportunistic infection . Must end acute therapy least 14 day prior study entry . Peripheral neuropathy = &gt; grade 2 . History intolerance 500 600 mg/day zidovudine ( AZT ) manifest recurrent grade 3 toxicity require dose interruption dose reduction &lt; 500 mg/day prior grade 4 toxicity . Prior development peripheral neuropathy ddI = &gt; grade 2 . Prior Medication : Excluded : Dideoxycytidine ( ddC ) . Required : Zidovudine ( AZT ) total least 24 week ; include within time period , AZT = &gt; 300 mg/day 6 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>